Infectious Diseases and Immunity: Special Reference to Major Histocompatibility Complex

Emerging Infectious Diseases

Volumn 3, Issue 1, 1997, Pages 41-49

  Singh, Neeloo ^a   Agrawal, S ^b   Rastogi, A K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

ALLELE; BACTERIAL INFECTION; COMMUNICABLE DISEASE; GENE FREQUENCY; GENETICS; HUMAN; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MYCOBACTERIOSIS; PARASITOSIS; REVIEW; VIRUS INFECTION;

ALLELES; BACTERIAL INFECTIONS; COMMUNICABLE DISEASES; GENE FREQUENCY; HLA ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MYCOBACTERIUM INFECTIONS; PARASITIC DISEASES; VIRUS DISEASES;

EID: 0030632180     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0301.970105     Document Type: Article

References (61)

1. McDevitt HO, Bodmer WF. Histocompatibility antigens, immune responsiveness and susceptibility to disease. Am J Med 1972;52:1-8.
2. Dausset J, Svejgaard A, editors. HLA and disease. Copenhagen:Munksgaard, 1977.
3. Stastny P, Ball EJ, Dry PJ, Nunez G. The human immune response region (HLA-D) and disease susceptibility. Immunol Rev 1983;70:111-54.
4. Tiwari JL, Terasaki PI, editors. HLA and disease association. New York: Springer 1985.
5. Hill AVS, Elvin J, Wills AC, Aidoo M, Allsopp CEM, Gotch FM, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992;360:434-9.
6. Assaad-Khalil SH, Helmy MAS, Zaki A, Mikhail MM, El-Hai MA, El-Sawy M. Some genetic, clinical and immunologic interrelations in schistosomiasis mansoni. Ann Biol Clin 1993;51:619-26.
7. Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci USA 1992;89:3932-6.
8. Powis SH, Tonks S, Mockridge I, Kelly AP, Bodmer JG, Trowsdale J. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics 1993;37:266-73.
9. Sant AJ, Miller J. MHC class II antigen processing: biology of invariant chain. Curr Opin Immunol 1994;6:57-63.
10. Kallmann FJ, Reisner D. Twin studies on the significance of genetic factors in tuberculosis. American Review of Tuberculosis 1943;47:549-74.
11. Bossik LJ. On the roles of hereditary and environment in the physiology and pathology of childhood tuberculosis. Proceedings of Maxim Gorky Medical Biology Research Institute (Moscow) 1934;19:111.
12. Nakamura RM, Tokunaga T. Strain difference of delayed type hypersensitivity to BCG and its genetic control in mice. Infect Immun 1978;78:657-64.
13. Rajalingam R, Mehra NK, Jain RC, Myneedu VP, Pande JN. Polymerase chain reaction-based sequence-specific oligonucleotide hybridization analysis of HLA class II antigens in pulmonary tuberculosis: relevance to chemotherapy and disease severity. J Infect Dis 1996;173:669-76.
14. Xu XP, Li SB, Wang CY, Li OH. Study on the association of HLA with pulmonary tuberculosis. Immunol Invest 1986;15:327-32.
15. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-9.
16. van Eden W, de Vries R, D'Amaro J. HLA-DR associated genetic control of the type of leprosy in a population from Surinam. Hum Immunol 1982;4:343-50.
17. Serjeantson S. HLA and susceptibility to leprosy. Immunol Rev 1983;70:89-112.
18. Ridley D, Jopling W. Classification of leprosy according to immunity. A five groups system. International Journal of Leprosy 1996;34:255-732.
19. van Eden W, Gonzales N, de Vries R, Convit J, van Rood J. HLA-linked control of predisposition of lepromatous leprosy. Infectious Diseases 1985;151:9-14.
20. Gorodezky C, Flores J, Arevalo N. Tuberculoid leprosy in Mexicans is associated with HLA-DR3. Lepr Rev 1987;58:401-6.
21. Rani R, Fernandez-Vina MA, Zaheer SA, Beena KR, Stastny P. Study of HLA class II alleles by PCR oligo-typing in leprosy patients from North India. Tissue Antigens 1993;42:133-7.
22. Hill AVS, Allsopp CEM, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. Common West African HLA antigens are associated with protection from severe malaria. Nature 1991;352:595-600.
23. Brown AE, Chandanayingyong D, Fuggle SV, Webster HK. Immune responses to the circumsporozoite protein of Plasmodium falciparum in relation to HLA-DR type. Tissue Antigens 1989;34:200-4.
24. Troye-Blomberg, Olerup O, Larsson A, Sjoberg K, Perlmann N, Riley E, et al. Failure to detect MHC class II associations of the human immune response induced by repeated malaria infections to the Plasmodium falciparum antigen Pf 155/RESA. Int Immunol 1991;3:1043-51.
25. Riley EM, Olerup O, Troye-Blomberg M. The immune recognition of malaria antigens. Parasitology Today 1991;7:5-11.
26. Morsy TA, Romia SA, al-Ganayni GA, Abu-Zakham AA, al-Shazly AM, Rezk RA. Histocompatibility antigens (HLA) in Egyptians with two parasitic skin diseases (scabies and leishmaniasis). J Egypt Soc Parasitol 1990;20:565-72.
27. Lara ML, Layrisse Z, Scorza JV, García E, Stoikaw Z, Granados J, et al. Immunogenetics of human American cutaneous leishmaniasis-study of HLA haplotypes in 24 families from Venezuela. Human Immunol 1991;30:129-35.
28. Assaad-Khalil SH, Helmy MAS, Zaki A, Mikhail MM, El-Hai MA, El-Sawy M. Some genetic, clinical and immunologic interrelations in schistosomiasis mansoni. Ann Biol Clin 1993;51:619-26.
29. Faghiri Z, Tabei SZ, Taheri F. Study of the association of HLA class I antigens with kala azar. Hum Hered 1995;45:258-61.
30. Singh N, Sundar S, Williams F, Curran MD, Rastogi A, Agrawal S, et al. Molecular typing of HLA class II DR antigens in Indian kala azar patients. Trop Med Int Health. In press.
31. Elston RC. Linkage and association to genetic markers Exp Clinical Immunogenetics 1995;12:3, 129-40.
32. Potts WK, Wakeland EK. The maintenance of MHC polymorphism. Immunology Today 1990;11:39-42.
33. Osaba D, Dick HM, Voller A, Goosen TJ, Goosen T, Draper C, et al. Role of the HLA complex in the antibody response to malaria under natural conditions. Immunogenetics 1979;8:323-38.
34. Falik K, Rotzsoke O, Stevanovic S, Jung G, Rammensee H. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 1991;351:290-6.
35. Jardetsky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991;353:326-9.
36. Elvin J, Cerundolo V, Elliot T, Townsend A. Quantitative assay of peptide dependent class I assembly. Eur J Immunol 1991;21:2025-31.
37. Yao Z, Maraskovsky E, Spriggs MK, Cohen JI, Armitage RJ, Alderson MR. Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation. J Immunol 1996;156:3260-6.
38. Becker Y. Computer simulations to predict the availability of peptides with known HLA class I motifs generated by proteolysis of dengue fever virus (DFV) type I structural and nonstructural proteins in infected cells. Virus Genes 1995;10:195-203.
39. Zeng L, Kurane I, Okamoto Y, Ennis FA, Brinton MA. Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones. J Virol 1996;70:3108-17.
40. Becker Y. Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs) - a novel approach to the protection of humans. Virus Genes 1994;9:33-45.
41. Winchester R, Chen Y, Rose S, Selby J, Borkowsky W. Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: determination by an automated sequence-based typing method. Proc Natl Acad Sci 1995;92:12374-8.
42. Bjork RL Jr. HIV-1: seven facets of functional molecular mimicry. Immunol Lett 1991;28:91-6.
43. Kamoun M, Zerva L, Sloan S, Zmijewski C, Monos D, Trinchieri G. Induction of HLA class II molecules on human T cells: relationship to immunoregulation and the pathogenesis of AIDS. DNA Cell Biol 1992;11:265-8.
44. Bisset LR. Molecular mimicry in the pathogenesis of AIDS: the HIV/MHC/mycoplasma triangle. Med Hypotheses 1994;43:388-96.
45. Yonemitsu Y, Nakagawa K, Tanaka S, Mori R, Sugimachi K, Sueishi K. In situ detection of frequent and active infection of human cytomegalovirus in inflammatory abdominal aortic aneurysms: possible pathogenic role in sustained chronic inflammatory reaction. Lab Invest 1996;74:723-36.
46. Beasley RP, Hwang LY, Lin CC, Chien CC. Hepatocellular carcinoma and hepatitis B virus. Lancet 1981;ii:1129-33.
47. Chen DS. From hepatitis to hepatoma: lessons learned from type B hepatitis. Science 1993;262:369-70.
48. Tsai SL, Chen MH, Yeh CT, Chu CM, Lin AN, Chiou FH, et al. Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. J Clin Invest 1996;97:577-84.
49. Davenport MP, Quinn CL, Chicz RM, Green BN, Willis AC, Lane WS, et al. Naturally processed peptides from two disease resistance associated HLA -DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain. Proc Natl Acad Sci 1995;92:6567-71.
50. Kurokochi K, Akatsuka T, Pendleton CD, Takamizawa A, Nishioka M, Battegay M, et al. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 1996;70:232-40 .
51. Peano G, Menardi G, Ponzetto A, Fenoglio LM. HLA-DR5 antigen. A genetic factor influencing the outcome of hepatitis C virus infection? Arch Intern Med 1994;154:23:2733-6.
52. Wolf H, Bogedain C, Schwarzmann F. Epstein-Barr virus and its interaction with the host. Intervirology 1993;35:26-39.
53. Lee SP, Morgan S, Skinner J, Thomas WA, Jones SR, Sutton J, et al. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur J Immunol 1995;25:102-10.
54. Hill A, Worth A, Elliott T, Rowland-Jones S, Brooks J, Rickinson A, et al. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. Eur J Immunol 1995;25:18-24.
55. Ferrone S, Yamamura M, Grosse-Wilde H, Pouletty P. Proceedings of the 11th International Histocompatibility Workshop. In: Tsuji K, Aizawa M, Sasazuki T, editors. Oxford Science Publications 1992;1057-61.
56. Alvarez-Cermeno JC, Casado C, Villar LM, Ferreira A, Varela JM, Dominguem, et al. Soluble class I antigens (SHLA) in CSF and serum of patients with HIV infection. Acta Neurol Scand 1990;82:14-6.
57. Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunology Today 1995; 16:124-7.
58. Verjans GM, Janssen R, UytdeHaag FG, van Doornik CE, Tommassen J. Intracellular processing and presentation of T cell epitopes, expressed by recombinant Escherichia coli and Salmonella typhimurium, to human T cells. Eur J Immun 1995; 25:405-10.
59. Scofield RH, Kurien B, Gross T, Warren WB, Harley JB. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthopathies. Lancet 1995; 345:1542-4.
60. Wakefield D, Montanaro A, McCluskey P. Acute anterior uveitis and HLA-B27. Surv Opthalmol 1991;36:223-32.
61. Sasazuki T. HLA-linked immune suppression genes. Jinrui Idengaku Zasshi 1990;35:1-13.